Young Ho Yoo is Chief Executive Officer of Celltrion Pharm, headquartered in South Korea, where he leads the company’s global strategy, operations, and expansion of contract manufacturing capabilities. Appointed CEO in 2024, he previously headed the company’s Chemical Manufacturing Division. Under his leadership, Celltrion Pharm signed a strategic agreement to expand its prefilled syringe CMO business and strengthen its international customer network. The company’s Cheongju, South Korea manufacturing facility is undergoing a major expansion expected to triple annual output by 2030, supporting global growth in oncology and biosimilars.
Yoo emphasizes ethical, compliance-driven management across all operations and leverages advanced manufacturing platforms to deliver high-quality solutions to pharmaceutical partners worldwide. His leadership positions Celltrion Pharm as a key South Korea–based player in global biopharmaceutical manufacturing and innovation.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential CEOs in Oncology in 2025 and stay tuned for other special category nominations
